# Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

> **NCT02104752** · PHASE1,PHASE2 · COMPLETED · sponsor: **VA Greater Los Angeles Healthcare System** · enrollment: 39 (actual)

## Conditions studied

- Schizophrenia
- Cognition
- Psychosis

## Interventions

- **DRUG:** Curcumin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02104752
- **Lead sponsor:** VA Greater Los Angeles Healthcare System
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-05
- **Final completion:** 2017-10
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-05-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02104752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02104752, "Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02104752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*